A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 22
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : IQ
Long Form : inhibitory quotient
No. Year Title Co-occurring Abbreviation
2016 High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. TAF, TAMs, TDF, TFV, TFV-DP
2016 Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester. LPV/RTV
2012 Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. ---
2012 The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans. CI, DAAs, HCV, LCIQ, PK-PD
2011 Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. CCM, CED, HCV, HP, PIs
2010 Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. HIV-1, IIP
2010 Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naive HIV-infected patients. IQR, PIs
2008 Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. AUC, HIV, NNRTI, SQV
2008 Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. HIV, PIs
10  2008 Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. gIQ, IQR, OBS, TPV, TPV-RTV, VL, VR
11  2007 Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. HAART, NRTIs, PGMs, PIs, RTV, SQV, VRs
12  2006 An update on therapeutic drug monitoring for antiretroviral drugs. ---
13  2005 Role of the inhibitory quotient in HIV therapy. gIQ, PIs
14  2004 Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome. ---
15  2004 Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. NRTIs
16  2004 Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. LPV, RTV
17  2004 [Monitoring of antibiotic treatment of patient with a severe bacterial infection]. MIC
18  2003 Evaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitis. AUC, AUIC, MIC
19  2003 Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. HIV
20  2003 Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? HAART, NNRTIs, NRTIs, PIs, TDM
21  2002 Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. AUC, MIC
22  2001 The 2nd International Workshop on Clinical Pharmacology of HIV Therapy. April 2nd-4th 2001, Noordwijk, The Netherlands. NNRTIs, PIs, TDM